kynostatin 272 has been researched along with HIV Coinfection in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (83.33) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maeda, Y; Mitsuya, H; Uchida, H | 1 |
| Anderson, BD; Balis, FM; Farley, MQ; Godwin, K; Jarosinski, P; McCully, CL; Mitsuya, H; Mueller, BU; Murphy, R; Pizzo, PA; Zuckerman, J | 1 |
| Fukasawa, T; Hayashi, H; Humphrey, RW; Kohler, DR; Mitsuya, H; Nguyen, BY; Shay, LE; Shintani, M; Steinberg, SM; Ueno, T; Wyvill, KM; Yarchoan, R | 1 |
| Churchill, DR; Gazzard, BG; Slade, PM; Weber, JN; Youle, M | 1 |
| Gold, D; Loftus, R | 1 |
3 trial(s) available for kynostatin 272 and HIV Coinfection
| Article | Year |
|---|---|
Pharmacokinetics of the protease inhibitor KNI-272 in plasma and cerebrospinal fluid in nonhuman primates after intravenous dosing and in human immunodeficiency virus-infected children after intravenous and oral dosing.
Topics: Administration, Oral; Adolescent; Animals; Child; Child, Preschool; Disease Models, Animal; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infusions, Intravenous; Macaca mulatta; Male; Oligopeptides | 1998 |
A phase I trial of the pharmacokinetics, toxicity, and activity of KNI-272, an inhibitor of HIV-1 protease, in patients with AIDS or symptomatic HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Dose-Response Relationship, Drug; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oligopeptides; RNA, Viral | 1999 |
A phase I/II study of the safety and activity of a microsphere formulation of KNI-272 in patients with HIV-1 infection.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Area Under Curve; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cohort Studies; Dose-Response Relationship, Drug; HIV Infections; HIV-1; Humans; Male; Microspheres; Middle Aged; Oligopeptides; Patient Dropouts; RNA, Viral; Treatment Outcome | 2001 |
3 other study(ies) available for kynostatin 272 and HIV Coinfection
| Article | Year |
|---|---|
HIV-1 protease does not play a critical role in the early stages of HIV-1 infection.
Topics: Chloramphenicol O-Acetyltransferase; HeLa Cells; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Oligopeptides; Ritonavir; Saquinavir | 1997 |
Kynostatin 272.
Topics: Adolescent; Child; Child, Preschool; Clinical Trials, Phase I as Topic; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Male; Oligopeptides | 1996 |
Protease inhibitors: where are they now?
Topics: Animals; Blood Proteins; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Industry; Drug Resistance; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Oligopeptides; Protein Binding; Pyrones; Quinolines; Rats; Saquinavir; Technology, Pharmaceutical; Urea; Warfarin; Zidovudine | 1995 |